Current Filters

Showing 21 - 30 results of 2970

Fentanyl Citrate (Abstral) (Last Updated: Jun 30, 2011)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Abstral
Manufacturer:
Paladin Labs Inc.
Submission Type:
Initial
Indications:

Pain, Cancer (breakthrough)

Fentanyl Citrate (Onsolis) (Last Updated: Aug 22, 2011)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Onsolis
Manufacturer:
Meda Valeant Pharma Canada Inc.
Submission Type:
Resubmission
Indications:

Pain (breakthrough), cancer (adults)

abobotulinumtoxinA (Dysport Therapeutic) (Last Updated: Jan 3, 2017)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Dysport Therapeutic
Manufacturer:
IPSEN Biopharmaceuticals Canada, Inc.
Submission Type:
Initial
Indications:

Cervical dystonia

Macitentan (Opsumit) (Last Updated: Dec 16, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Opsumit
Manufacturer:
Actelion Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Pulmonary arterial hypertension

Eplerenone (Inspra) (Last Updated: Jul 12, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Inspra
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Heart failure, NYHA class II

Download results as CSV